HDM201 + cytarabine + anthracycline + midostaurin

This drug is a **four-drug combination regimen** composed of HDM201 (siremadlin), cytarabine, an anthracycline (such as daunorubicin or idarubicin), and midostaurin. - **HDM201 (siremadlin)** is a **second-generation MDM2-p53 interaction antagonist** that stabilizes p53, promoting p53-dependent apoptosis in malignant cells with wild-type TP53[1][5][3]. - **Cytarabine** is a **pyrimidine nucleoside antimetabolite** that inhibits DNA synthesis, leading to cell death, especially in rapidly dividing cells. - **Anthracyclines** (e.g., daunorubicin, idarubicin) are **topoisomerase II inhibitors** that intercalate DNA and induce DNA breaks, causing apoptosis in cancer cells. - **Midostaurin** is a **multitargeted kinase inhibitor** that inhibits receptor tyrosine kinases including FLT3, c-KIT, and PDGFR, leading to apoptosis in AML cells, particularly those with FLT3 mutations[4][2][6][8][3]. This regimen's primary indication is **acute myeloid leukemia (AML)**, especially in patients with FLT3 mutations and wild-type TP53[3]. It is currently under evaluation in clinical trials for relapsed/refractory AML, with phase I development status[3]. Developers include Novartis.

Brand names

Rydapt (midostaurin)

Other names

HDM201HDM-201HDM 201siremadlincytarabineanthracycline (e.g., daunorubicin, idarubicin)midostaurinPKC412PKC-412PKC 412NVP-PKC412NVP-PKC-412NVP-PKC 412